Treatment satisfaction with botulinum toxin: a comparison between blepharospasm and cervical dystonia

Figures & data

Table 1 Patient’s demographics and characteristics

	Cervical dystonia	Blepharospasm	P-value
Female, n (%)	243 (66.8)	79 (56.3)	ns
Mean age (n, SD, range)	56.5 (359, 12.5; 20–91)	65.2 (121, 12.7; 24–87)	<0.0001
Age group (years), n (%)
25–34	21 (5.9)	1 (0.8)
35–44	27 (7.5)	9 (7.5)
45–54	112 (31.3)	16 (13.3)
55–64	106 (29.6)	20 (16.7)
≥65	92 (25.7)	74 (61.7)
Mean years of education (n, SD, range)	11.1 (327, 3.9; 8–19)	10.8 (105, 3.6; 8–19)	ns

Abbreviation: ns, not significant.

Table 2 Patient’s work situation

	Cervical dystonia	Blepharospasm	P-value
Retirement not associated with dystonia, n (%)	191 (52.0)	89 (74.2)	<0.0001
Reduction of weekly work hours, n (%)	85 (25.6)	20 (18.7)	ns
Shifting type of work because of dystonia, n (%)	48 (14.5)	8 (7.1)	0.042
Decreased efficacy at work because of dystonia, n (%)	180 (55.7)	41 (37.3)	<0.001
Unemployment due to dystonia, n (%)	56 (16.0)	8 (7.3)	0.021
Restored capacity to work because of BoNT, n (%)	141 (47.2)	33 (36.7)	0.079

Abbreviations: BoNT, botulinum toxin; ns, not significant.

Figure 1 Course of dystonia over years: subjective perception (%).

Table 3 Medical variables and BoNT treatment characteristics

	Cervical dystonia	Blepharospasm	P-value
Mean years since diagnosis of dystonia (n, SD, range)	10.6 (336, 8.4; 0.26–4.41)	9.3 (117, 6.4; 0.19–27.4)	ns
Mean years since first signs of dystonia (n, SD, range)	13.8 (354, 9.9; 0.26–53.3)	12.5 (117, 9.8; 0.63–73.2)	ns
Mean years of BoNT (n, SD, range)	8.8 (342, 6.7; 0.18–34.3)	8.2 (120, 6.3; 0.10–27.4)	ns
Mean weeks between injections (n, SD, range)	12.1 (358, 2.1; 4.00–28.0)	11.8 (121, 3.4; 2.0–24.0)	ns
Mean no of injections until optimal response (n, SD, range)	3.9 (198, 3.1; 1.00–25.0)	3.2 (52, 2.3; 1.0–11.0)	ns
Emotional hassles prior to dystonia (n, %)	84 (23.9)	29 (24.4)	ns
Mental disorders prior to dystonia (n, %)	69 (19.8)	26 (22.0)	ns
Mean years of emotional hassles/mental disorders prior to diagnosis (n, SD, range)	7.36 (58, 10.80; 0.00–66)	7.74 (19, 10.5; 0.00–31)	ns

Abbreviations: BoNT, botulinum toxin; ns, not significant.

Figure 2 Expectations about botulinum toxin therapy (%).

Figure 3 Perceived efficacy of botulinum toxin therapy (%).

Note: 1= best outcome, 6= worst outcome.

Figure 4 Perceived BoNT effect within treatment cycles (mean).

Note: 1= best outcome, 6= worst outcome.
Abbreviation: BoNT, botulinum toxin.

Figure 5 Satisfaction with BoNT treatment, symptom severity, psychosocial situation, and quality of life (mean).

Note: 1= extremely satisfied, 6= not at all satisfied.
Abbreviation: BoNT, botulinum toxin.